Comparative Pharmacology
Head-to-head clinical analysis: KAFOCIN versus VELOSEF 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KAFOCIN versus VELOSEF 250.
KAFOCIN vs VELOSEF '250'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KAFOCIN (cefepime/enmetazobactam) is a combination of a fourth-generation cephalosporin (cefepime) and a β-lactamase inhibitor (enmetazobactam). Enmetazobactam inhibits extended-spectrum β-lactamases (ESBLs) and other class A β-lactamases, restoring cefepime's activity against β-lactamase-producing bacteria. Cefepime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
Bactericidal antibiotic that inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically inhibiting transpeptidase activity, leading to cell lysis.
1 g IV every 8 hours.
250 mg orally every 6 hours for adults with normal renal function.
None Documented
None Documented
Terminal elimination half-life: 4.5-6.5 hours (increased to 12-18 hours in severe renal impairment; CrCl <30 mL/min).
1.2-1.5 hours in normal renal function; prolonged in renal impairment (up to 10-20 hours in ESRD)
Renal: 60-80% unchanged; biliary/fecal: 15-30% as metabolites; total clearance ~120 mL/min.
Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); remainder biliary/fecal (<10%)
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic